MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Abbott Laboratories

Atidarymo kaina

SektoriusSveikatos priežiūra

128.32 -0.9

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

127.11

Max

130.1

Pagrindiniai rodikliai

By Trading Economics

Pajamos

7.6B

9.2B

Pardavimai

339M

11B

P/E

Sektoriaus vid.

17.001

57.333

Pelnas, tenkantis vienai akcijai

1.09

Dividendų pajamingumas

1.8

Pelno marža

84.099

Darbuotojai

114,000

EBITDA

82M

3B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+11.42% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.80%

2.63%

Kitas dividendų mokėjimo data

2025-05-15

Kita Ex Dividend data

2025-07-14

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

3B

225B

Ankstesnė atidarymo kaina

129.22

Ankstesnė uždarymo kaina

128.32

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Abbott Laboratories Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-16 16:21; UTC

Uždarbis

Abbott Labs Bracing for Tariffs as Profits Rise -- Update

2025-04-16 12:14; UTC

Uždarbis

Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices

2025-01-22 19:03; UTC

Uždarbis

Correction to Abbott Labs 4Q Sales Just Miss Estimates Article

2025-01-22 18:20; UTC

Uždarbis

Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update

2025-01-22 12:45; UTC

Uždarbis

Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales

2025-04-16 15:09; UTC

Rinkos pokalbiai

Abbott Says Tariffs Killed Chances of an Outlook Raise -- Market Talk

2025-04-16 14:17; UTC

Uždarbis

Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations -- Barrons.com

2025-04-16 11:34; UTC

Uždarbis

Abbott Labs 1Q Gross Margin of 52.8 % of Sales; Adj Gross Margin of 57.1 % >ABT

2025-04-16 11:33; UTC

Uždarbis

Abbott Labs Projects FY25 Adj Operating Margin to Be 23.5% to 24.0% of Sales >ABT

2025-04-16 11:32; UTC

Uždarbis

Abbott Labs Backs FY25 Adj EPS $5.05-Adj EPS $5.25 >ABT

2025-04-16 11:32; UTC

Uždarbis

Abbott Labs Sees 2Q Adj EPS $1.23-Adj EPS $1.27 >ABT

2025-04-16 11:31; UTC

Uždarbis

Abbott Labs Projects FY25 Organic Sales Growth of 7.5% to 8.5% >ABT

2025-04-16 11:30; UTC

Uždarbis

Abbott Reaffirms Full-Yr Guidance

2025-04-16 11:30; UTC

Uždarbis

Abbott Labs 1Q Organic Sales Growth Up 6.9% >ABT

2025-04-16 11:30; UTC

Uždarbis

Abbott Labs 1Q Sales $10.36B >ABT

2025-04-16 11:30; UTC

Uždarbis

Abbott Labs 1Q Net $1.33B >ABT

2025-04-16 11:30; UTC

Uždarbis

Abbott Labs 1Q EPS 76c >ABT

2025-04-16 11:30; UTC

Uždarbis

Abbott Labs 1Q Adj EPS $1.09 >ABT

2025-04-16 09:57; UTC

Karštos akcijos

Stocks to Watch: Nvidia, AMD, Heineken, ASML -- WSJ

2025-02-01 18:14; UTC

Svarbiausios naujienos

Musk's X Adds Nestlé, Colgate, Shell, Other Brands to Ad-Boycott Suit -- WSJ

2025-01-22 16:40; UTC

Svarbiausios naujienos
Uždarbis

Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings. -- Barrons.com

2025-01-22 15:20; UTC

Uždarbis

Abbott Laboratories Posts 'Middling' Quarter, But Diabetes Devices Shine -- IBD

2025-01-22 15:08; UTC

Uždarbis

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

2025-01-22 13:51; UTC

Uždarbis

Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit -- IBD

2025-01-22 13:39; UTC

Svarbiausios naujienos
Uždarbis

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

2025-01-22 12:02; UTC

Uždarbis

Abbott Labs Sees 1Q Adj EPS $1.05-Adj EPS $1.09 >ABT

2025-01-22 12:01; UTC

Uždarbis

Abbott Labs Sees 2025 Adj EPS $5.05-Adj EPS $5.25 >ABT

2025-01-22 12:01; UTC

Uždarbis

Abbott Labs Sees 2025 Adjusted Operating Margin 23.5%-24% >ABT

2025-01-22 12:00; UTC

Uždarbis

Abbott Labs Sees 2025 Organic Sales Growth 7.5%-8.5% >ABT

2025-01-22 12:00; UTC

Uždarbis

Abbott Labs 4Q Net $9.23B >ABT

Akcijų palyginimas

Kainos pokytis

Abbott Laboratories Prognozė

Kainos tikslas

By TipRanks

11.42% į viršų

12 mėnesių prognozė

Vidutinis 144.15 USD  11.42%

Aukščiausias 159 USD

Žemiausias 127 USD

Remiantis 21 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Abbott Laboratories kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

21 ratings

18

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

128.52 / 129.7Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.